Hem › Burkitts lymfom › Alabama
Kliniska studier för Burkitts lymfom i Alabama
7 studier för Burkitts lymfom söker deltagare vid platser i Alabama.
Städer i Alabama
Officiell studietext (engelska)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital of Alabama, Birmingham
RekryterarFas 2
366 Days – 46 Years · Alla kön · Uppdaterad 2 okt. 2026 · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Hospital of Alabama, Birmingham
RekryterarFas 2
365 Days · Alla kön · Uppdaterad 25 sep. 2026 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital of Alabama, Birmingham
- USA Health Strada Patient Care Center, Mobile
RekryterarFas 2
Ålder 1 till 30 · Alla kön · Uppdaterad 1 sep. 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Hospital of Alabama, Birmingham
- USA Health Strada Patient Care Center, Mobile
RekryterarFas 3
365 Days – 25 Years · Alla kön · Uppdaterad 25 aug. 2026 · NCT03959085Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- University of Alabama at Birmingham, Birmingham
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 5 nov. 2025 · NCT04260022The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Children's of Alabama/University of Alabama in Birmingham(UAB), Birmingham
RekryterarFas 2
Ålder 1 till 25 · Alla kön · Uppdaterad 4 maj 2025 · NCT03509961Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- University of Alabama at Birmingham, Birmingham
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 15 nov. 2024 · NCT06034275Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.